These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 36428761)
1. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Kurita Y; Kobayashi N; Hara K; Mizuno N; Kuwahara T; Okuno N; Haba S; Tokuhisa M; Hasegawa S; Kubota K; Nakajima A; Ichikawa Y Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428761 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms. Kurita Y; Kobayashi N; Hara K; Mizuno N; Kuwahara T; Okuno N; Haba S; Tokuhisa M; Hasegawa S; Sato T; Hosono K; Kato S; Kessoku T; Endo I; Shimizu Y; Kubota K; Nakajima A; Ichikawa Y; Niwa Y Intern Med; 2023 Jan; 62(2):159-167. PubMed ID: 35705270 [TBL] [Abstract][Full Text] [Related]
3. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms. Quan L; Liu Y; Cui W; Wang X; Zhang W; Wang Z; Guo C; Lu C; Hu F; Chen X Lipids Health Dis; 2022 Jul; 21(1):58. PubMed ID: 35842659 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea. Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443 [TBL] [Abstract][Full Text] [Related]
6. A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The 'PROTOR' Study. Kaltsas G; Andreadis C; Kosmidis P; Mavroudis D; Pazaitou-Panayiotou K; Vaslamatzis M; Athanasiadis I Anticancer Res; 2022 Apr; 42(4):1941-1948. PubMed ID: 35347014 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503 [TBL] [Abstract][Full Text] [Related]
8. Everolimus for advanced pancreatic neuroendocrine tumors. Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K; N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238 [TBL] [Abstract][Full Text] [Related]
9. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887 [TBL] [Abstract][Full Text] [Related]
10. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254 [TBL] [Abstract][Full Text] [Related]
11. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796 [TBL] [Abstract][Full Text] [Related]
12. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. Guo C; Zhuge X; Wang Z; Wang Q; Sun K; Feng Z; Chen X Abdom Radiol (NY); 2019 Feb; 44(2):576-585. PubMed ID: 30182253 [TBL] [Abstract][Full Text] [Related]
13. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834 [TBL] [Abstract][Full Text] [Related]
14. Outcome and safety of rechallenge [ Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706 [TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial). Okuyama H; Ikeda M; Okusaka T; Furukawa M; Ohkawa S; Hosokawa A; Kojima Y; Hara H; Murohisa G; Shioji K; Asagi A; Mizuno N; Kojima M; Yamanaka T; Furuse J Neuroendocrinology; 2020; 110(11-12):988-993. PubMed ID: 31986515 [TBL] [Abstract][Full Text] [Related]
16. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987 [TBL] [Abstract][Full Text] [Related]
17. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Fazio N; Buzzoni R; Delle Fave G; Tesselaar ME; Wolin E; Van Cutsem E; Tomassetti P; Strosberg J; Voi M; Bubuteishvili-Pacaud L; Ridolfi A; Herbst F; Tomasek J; Singh S; Pavel M; Kulke MH; Valle JW; Yao JC Cancer Sci; 2018 Jan; 109(1):174-181. PubMed ID: 29055056 [TBL] [Abstract][Full Text] [Related]
18. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065 [TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907 [TBL] [Abstract][Full Text] [Related]
20. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Fazio N; Carnaghi C; Buzzoni R; Valle JW; Herbst F; Ridolfi A; Strosberg J; Kulke MH; Pavel ME; Yao JC Cancer; 2021 Aug; 127(15):2674-2682. PubMed ID: 33857327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]